Chelsea Therapeutics, formerly known as Aspen Therapeutics and a newcomer to Charlotte, is filling out its management team with a series of new hires.

The firm has named a vice president for drug development, a chief financial officer, a director of business development and a director of drug development.

Chelsea changed its named and relocated to Charlotte in July.

L. Arthur Hewitt is the vice president of drug development. He has more than 25 years of experience in pharmaceuticals, having worked for Abbott Laboratories, Parke-Davis, Janssen Pharmaceuticals and Amgen. At Amgen, he oversaw approval of the drugs Neupogen, Stemgen and Infergen, according to Chelsea.

J. Nick Riehle is the vice president for administration and CFO. Riehle worked for HAHT Commerce in Raleigh as well as Nortel and IBM.

Michael Roberts is the director of business development. He worked previously for Nektar Therapeutics where he led business development efforts for molecule engineering technology.

Cameron Szakacs is the associate director of drug development. He also worked at Nektar where he directed preclinical programs. Szakacs also worked five years at Hoffman La Roche.

“We are committed to building a world-class team with exceptional competencies in clinical, regulatory and business development. I am delighted with the progress we have made in assembling just such a team,” said Simon Pedder, the company’s president and CEO, in a statement.

Pedder joined Chelsea in May. His most recent position was vice president of pharmaceutical business, oncology, at Hoffmann-La Roche.
Chelsea describes itself as a development stage biopharmaceutical company that acquires and develops innovative products for the treatment of a variety of human diseases, including rheumatoid arthritis, psoriasis and cancer.

Its lead molecule, called CH-1504, is in preclinical trials.

Chelsa: www.chelseatherapeutics.com